The present study included newly diagnosed, untreated, KRAS wt, advanced CRC patients who responded to FOLFORI-cetuximab for much longer periods and who therefore allowed us to gather, for the first time, valuable data related to the use of liquid biopsy in mCRC patients who displayed prolonged responses to first-line anti-EGFR therapy. The gene discussed is KRAS; the disease is colorectal carcinoma.